Lymphomas clinical trials

Explore recruiting lymphomas clinical trials.

Recruiting lymphomas studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lymphomas trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase III Randomized Double-Blinded Placebo-Controlled Study of Use of GnRHa during Chemotherapy for Fertility Protection of Young Women and Teenagers with Cancer - ProFertil

Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

A PHASE 2 OPEN LABEL STUDY OF ORAL LORLATINIB (PF-06463922) IN PATIENTS WITH RELAPSED ALK POSITIVE LYMPHOMA PREVIOUSLY TREATED WITH ALK INHIBITORS

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

BeCALM - Brentuximab vedotin in CutAneous T-cell Lymphomas (CTCL): post-allogeneic hematopoietic stem cell transplant Maintenance

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomized study to protect from radiation iatrogenic hypothyroidism patients with medulloblastoma (any stage, any biological risk) and pediatric patients with Hodgkin lymphoma and non-Hodgkin lymphoma needing radiation therapy on thyroid site - WINHYPO 2021

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

TRANSCRIPT: An open label, controlled, randomized multicentric international study evaluating the benefit of autologous stem cell transplantation after complete response in frontline setting patients with T cell-lymphoma

Belgium, France

Therapeutic use (Phase IV) EU CTIS Study details

BiCAR Therapy - A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas after CAR T-cells therapy

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Lymphomas trials by city

Lymphomas in Toronto Lymphomas in Vancouver Lymphomas in Montreal Lymphomas in Calgary Lymphomas in Edmonton Lymphomas in Ottawa Lymphomas in Winnipeg Lymphomas in Quebec City Lymphomas in Hamilton Lymphomas in Kitchener Lymphomas in London Lymphomas in Halifax Lymphomas in New York Lymphomas in Los Angeles Lymphomas in Chicago Lymphomas in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease